GRAL
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
Article Summary
BUY- GRAIL Inc. (Nasdaq: GRAL) presented PATHFINDER 2 results showing Galleri Multi-Cancer Early Detection Test significantly increased cancer detection with robust performance and favorable safety at 2026 ASCO Annual Meeting, with more than half of new cancers detected by Galleri detected as stage I or II and 71.3% with no USPSTF A or B recommended screening.
- GRAIL's largest interventional study of an MCED in North America includes 35,878 participants in broad, intended-use population of adults aged 50 and older with no clinical suspicion of cancer, with 60% of diagnosed cancers being screen-detected.
- Adding Galleri to recommended screenings for breast, cervical, colorectal, and lung cancers led to a 6.5 fold increase in the number of cancers found by screening, with 70.9% of all cancers detected at stages I-III when treatment with curative intent is more often possible.
- While effective screening improves early cancer detection, in the U.S.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 19.4% | 25% | 60.0 ptsModerate (19.4%) - Decent growth |
| EPS Growth Next 5Y ? | 2.7% | 25% | 10.0 ptsVery Weak (2.7%) - Minimal expectations |
| Target Price Upside ? | 6.7% | 20% | 10.0 ptsNear/At Target (6.7%) - Target: $66.86 vs Current: $71.68 |
| Gross Margin % ? | -44.7% | 15% | 10.0 ptsRazor-Thin (-44.7%) - Weak pricing power |
| Drawdown from 52-Wk High ? | -39.7% | 15% | 80.0 ptsSolid Dip (-39.7%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About GRAL
- GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
- It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
- The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.
- In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring.
- The company was incorporated in 2015 and is headquartered in Menlo Park, California.